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Abstract
Cancer therapeutics include an ever-increasing array of tools at the disposal of clinicians in their
treatment of this disease. However, cancer is a tough opponent in this battle and current treatments
which typically include radiotherapy, chemotherapy and surgery are not often enough to rid the
patient of his or her cancer. Cancer cells can become resistant to the treatments directed at them and
overcoming this drug resistance is an important research focus. Additionally, increasing discussion
and research is centering on targeted and individualized therapy. While a number of approaches have
undergone intensive and close scrutiny as potential approaches to treat and kill cancer (signaling
pathways, multidrug resistance, cell cycle checkpoints, anti-angiogenesis, etc.), much less work has
focused on blocking the ability of a cancer cell to recognize and repair the damaged DNA which
primarily results from the front line cancer treatments; chemotherapy and radiation. More recent
studies on a number of DNA repair targets have produced proof-of-concept results showing that
selective targeting of these DNA repair enzymes has the potential to enhance and augment the
currently used chemotherapeutic agents and radiation as well as overcoming drug resistance. Some
of the targets identified result in the development of effective single-agent anti-tumor molecules.
While it is inherently convoluted to think that inhibiting DNA repair processes would be a likely
approach to kill cancer cells, careful identification of specific DNA repair proteins is increasingly
appearing to be a viable approach in the cancer therapeutic cache.
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INTRODUCTION
Cancer therapeutics include an ever-increasing array of tools at the disposal of clinicians in
their treatment of this disease. However, cancer is a tough opponent in this battle, and current
treatments are too frequently not enough to rid the patient of his or her cancer. In some cancers,
such as pediatric leukemia, there have been dramatic improvements in survival, however in
others, such as pancreatic cancer, the survival rate remains a dismal four percent [1]. Clearly
new and innovative approaches need to be investigated. One such approach that is gaining
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interest and enthusiasm in the treatment of cancer is rationally designed therapy toward specific
molecular targets such as growth factor receptors, cell cycle proteins, etc. While much more
is known about intervention into other pathways (signaling pathways, multidrug resistance,
cell cycle checkpoints, anti-angiogenesis, etc.) as potential approaches to treat and kill cancer,
much less work has focused on blocking the ability of a cancer cell to recognize and repair the
damaged DNA which results from front line cancer treatments; chemotherapy and radiation.
Both types of treatments induce DNA damage which is acted upon by a variety of DNA repair
pathways. Critical steps within these pathways are emerging as potential targets and could be
utilized to either enhance the current standard of care i.e. chemotherapy and radiation or to
partner with other small molecules directed at specific targets and pathways mentioned above.
While agents that inhibit DNA repair have not received a significant amount of attention as a
cancer therapeutic, more recently it has become a major area of research. Studies in DNA repair
have long been conducted by outstanding biochemists and molecular biologists, but translating
these findings to the clinic for cancer therapeutics has lagged significantly. Moreover, the field
of DNA repair has extended dramatically from its original description as enzymes that interact
directly with the damaged base or DNA to include numerous signaling pathways such as
BRCA1 and 2 (breast cancer gene 1 and 2), FANC (fanconi anemia complementation group
C), ATM (Ataxia telangiectasia) and others. The main focus of this review will be on the
enzymes in DNA repair pathways that act upon the damaged DNA substrate. While it is
inherently convoluted to think that inhibiting DNA repair processes would be a feasible
approach to kill cancer cells, careful identification of DNA repair proteins with crucial roles
in preserving DNA integrity is a seemingly viable approach in the cancer therapeutic cache.
The major DNA repair pathways include direct (O6-alkylguanine DNA methyltransferase,
AGT), base excision (BER), nucleotide excision (NER), mismatch (MMR), homologous (HR)
and non-homologous end-joining (NHEJ) repair. While all pathways will be discussed, the
main focus of this review will be on BER and direct repair as pathways with rationale
therapeutic targets. The reason for this is straight-forward; existing evidence suggests that both
pathways contain proteins that are reasonable, clinically relevant targets. Other pathways, such
as MMR and NER, for example, do not have as much compelling data to suggest clinical
applicability. Furthermore, given previous findings that knocking out, down or mutating
members of the MMR or NER pathways can lead to serious diseases such as hereditary non-
polyposis colon cancer (HNPCC) [2] or Xeroderma pigmentosum (XP) [3], respectively, the
rationale for targeting members of these pathways is more strained. That being said, new tumor
cell targeting approaches could overcome these difficulties. For a comprehensive review of
the other pathways and ancillary pathways related to DNA repair, readers are encouraged to
investigate the review by Belzile, et al. [4]. Additionally, some other careful reviews have
appeared relating to DNA repair and therapeutics and readers of this review are encouraged to
read them [5-8].
DIRECT REPAIR
The direct repair pathway is typified by O6-alkylguanine DNA methyltransferase (AGT) which
plays an important biological role in directly repairing O6-alkylguanine in DNA [5]. Elevated
levels of AGT in tumors correlate to resistance [9] making AGT one of the first DNA repair
targets identified for cancer therapeutics [10]. Additionally, AGT has potential usefulness in
gene therapy protocols to protect against side effects of cancer chemotherapy such as
myelosuppression [9-11]. Ideally, inhibition of this protein in tumors would sensitize the
tumors to chemotherapeutic agents that generate lesions at the O6-position of guanine. AGT
is a protein and not an enzyme since it preferentially removes one alkyl group from the O6-
position of guanine to its active site, rendering it inactive, and is subsequently degraded (Fig.
1A).
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Chemotherapeutic agent, BCNU (1,3-bis (2-chloroethyl)-1-nitrosourea) generates chloroethyl
modifications at O6, which can rearrange and lead to an interstrand cross-link [12]. Interstrand
DNA crosslinks are particularly cytotoxic because they block DNA replication. AGT repairs
DNA damage following chloroethylating and methylating agents such as BCNU which
generates several DNA adducts including O6-methylguanine (O6-meG). O6-meG
preferentially pairs with thymine and leads to GC to AT transitions [10,13]. Inhibition of AGT
leads to sensitization to BCNU as the cells are unable to repair the lesion on the O6-postion of
guanine which then leads to subsequent interstrand crosslink formation. However, more
recently, interest has centered on the role of AGT in the response of patients to temozolomide
(TMZ) treatment which is a recently developed chemotherapeutic alternative to BCNU for
patients with astrocytoma, glioblastoma, metastatic brain tumors and malignant melanoma
[14]. TMZ methylates DNA at the N7 and O6-positions of guanine and N3 of adenine [15]
generating lesions that are repaired by both the AGT and BER pathways [16]. Inhibition of
AGT in conjunction with TMZ treatment also leads to tumor cell sensitization [10,17-19].
Furthermore, several research groups have focused their efforts on the manipulation of AGT
to sensitize tumor cells to alkylating agents while protecting the bone marrow compartment
from the characteristic myelosuppression associated with chemotherapy. Hematopoietic bone
marrow progenitor cells are protected by gene transfer of mutant AGT protein(s) that are
resistant to inhibition due to an alteration of their active site [20-22]. This chemo-sensitive
compartment is protected while inhibiting the tumor cell AGT and thereby increasing
alkylating agent sensitivity and efficacy.
As mentioned, agents such as streptozotocin, procarbazine, dacarbazine, BCNU, CCNU (1-2-
chloroethyl-3-cyclohexyl-1-nitrosourea) and TMZ generate lesions at the O6-position of
guanine making AGT a target to inhibit in combination with these drugs [17]. The therapeutic
approach has been to treat tumor cells or patients with an agent such as O6-benzyguanine (BG)
which acts as a pseudo-substrate and renders AGT inactive to repair the DNA damage in the
tumor cell (Fig. 1A). An orally bioavailable BG analogue, O6-(4-bromothenyl)-guanine (O6-
BTG) appears to be more than ten times more potent than BG [23]. Recently, a clinical trial
using [6-(4-bromo-2-thienyl) methoxy]purin-2-amine] or Lomeguatrib along with TMZ
demonstrated significant efficacy in the reduction of AGT levels in the 23 patients with
advanced solid tumors, with one complete response and 12 patients with stable disease for at
least three months [24]. As expected, the dose limiting toxicity of the combination of
lomeguatrib and TMZ was myelosuppression. Other molecules with similar mechanisms of
action as BG include O6-benzyl-2'-deoxyguanosine which has improved potency and solubility
and O6-4-bromothenylguanine-C8-B-d-glucoside which is a glucose conjugate with tumor-
targeting action due to the selective uptake of glucose by tumors. The latter has been shown
to have activity against TMZ and fotemustine in vitro [25]. A number of clinical trials have
opened using BG and analogues on a wide variety of tumors including glioma, lymphoma,
myeloma, melanoma, colon cancer, sarcoma and others [5,17,9].
Finally, unexpected or off-target effects of BG have recently been identified [26-28]. In an
elegant series of experiments, head and neck tumor cell lines pretreated with BG resulted in a
2-fold decrease in the ED50 of cisplatin and a concomitant increase in DNA damage and in the
percentage of cells undergoing apoptosis. The enhancement was independent of AGT activity.
Similar enhancement was observed with carboplatin, but no enhancement was seen in AGT-
deficient cell lines with radiation or TMZ, demonstrating the dependence of the effect on
bifunctional, cross-linking agents [26]. Additional studies have ruled out the role of glutathione
(GSH) or NER pathways for this increase in cytoxicity observed using BG with cisplatin
[27,28]. However, it was recently shown that cyclin-dependent kinase (CDK)2 pathway is
affected by a number of guanine derivatives which inhibit CDK2 and enhances cisplatin
cytotoxic and apoptotic effects. This group includes BG although it was not the most potent
enhancer of cisplatin-induced cytotoxicity [27].
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BG is currently being used as a modulator of BCNU, Gliadel, and TMZ in Phase II and III
clinical trials. To date, there have been no significant toxicities associated with BG when it is
administered alone to humans [29-33]. The development of BG as a DNA repair inhibitor is a
great example of bench research resulting in clinical application.
BASE EXCISION REPAIR (BER)
Within mammalian BER there are two branches: long patch (LP) and short patch (SP), and
they differ in the proteins involved as well as in the length of DNA that is synthesized during
the repair process. The mechanism of which pathway is chosen in the cell is still under
investigation but the type of damage and the glycosylase that removes the damage are involved
[34,35]. The predominant BER pathway, SP-BER repairs an oxidized or alkylated base
beginning with a DNA glycosylase (e.g. methylpurine DNA glycosylase or MPG also called
AAG) which removes the damaged base, leaving the DNA backbone intact. The second
enzyme in this pathway, Apurinic endonuclease 1 / Redox factor-1 (APE1/Ref-1), hydrolyzes
the phosphodiester backbone immediately 5' to an abasic site (reviewed in [36]). Oxidation
and alkylation of DNA bases as well as abasic sites are generated following chemotherapeutic
treatment. The APE1/Ref-1 incision generates a normal 3'-hydroxyl group and an abasic
deoxyribose-5-phosphate, which is processed by subsequent enzymes of the BER pathway,
β-polymerase (β-pol) and DNA Ligase III/XRCC1. LP-BER functions to resolve oxidized or
reduced abasic sites and involves APE1/Ref-1 incision activity as well. Polymerases δ and ε,
PCNA, and RFC can provide gap filling DNA synthesis as well as βpol. Flap endonuclease
(FEN1) cleaves the displaced oligonucleotide, and Ligase I seals the nicks (Fig. 1B) (reviewed
in [35]. Both pathways are important for the survival and integrity of DNA sequence to cells.
Likewise, manipulation of both pathways by a tumor cell could impart resistance to
chemotherapeutic agents that generate alkylation and oxidative damage. Some examples of
chemotherapeutic agents that generate lesions that BER would repair include: temozolomide
[37], melphalan [38], thiotepa [39], methyl-lexitropsin (Me-lex) [40], dacarbazine /
procarbazine [41], and streptozotocin [42] (Table 1). Some chemotherapeutic agents generate
reactive oxygen species (ROS) as a “by-product” such as platinum-based drugs i.e. oxaliplatin
and cisplatin [43,44], anthracyclines i.e. epirubicin, daunorubicin, doxorubicin [45] and
paclitaxel [46,47] indicating that BER may be important in the response to these drugs as well
(Table 1). Ionizing radiation (IR) creates lesions on DNA that are acted upon by the BER
pathway and is used extensively in cancer therapy regimens (reviewed in [48]), yet another
indication that inhibition of the BER pathway will have clinical implications and efficacy.
Glycosylases
The first step in repairing a single base lesion in DNA is the removal of the damaged base and
is achieved by numerous glycosylases which are specific for the type of DNA lesion that is in
need of repair. For example, methylpurine DNA glycosylase (MPG, AAG), 8-oxoguanine
DNA glycosylase (OGG1), uracil DNA glycosylase (UNG), Thymine DNA glycosylase
(TDG), etc remove specific lesions as their names suggest (reviewed in [49]). Based on the
diversity of lesions and glycosylases that recognize them, this may not be the ideal step to target
in attempts to sensitize cancer cells to DNA damaging agents. There is a report that divalent
ions, Cd2+, Ni2+, and Zn2+ can inhibit MPG [50]. In addition, reduced levels of MPG protein
using siRNA increased the sensitivity of cervical carcinoma cell lines to TMZ, MMS, N-
methyl-N-nitrosourea, and BCNU [51]. However there are several reports that overexpressing
this glycosylase is deleterious to cancer cells demonstrating that there is a delicate balance
within the BER pathway that can be exploited to kill tumor cells [52-55]. Abasic sites are
generated following glycosylase removal of a damaged base and there is only one enzyme that
processes abasic sites – APE1/Ref-1, indicating that it may be a better therapeutic target than
the glycosylases.
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APE1/Ref-1
The DNA repair activity of APE1/Ref-1 is fundamental to the maintenance of the genome and
survival of cells. Even in the absence of exogenous DNA damage, siRNA directed against
APE1/Ref-1 results in a decrease in proliferation, an increase in AP sites and increased levels
of apoptosis [56].The expression of APE1/Ref-1 is altered in numerous cancers including
prostate, ovarian, cervical, germ cell tumor, rhabdomyosarcoma, and colon [36]. APE1/Ref-1
is an essential enzyme in the BER pathway which is responsible for the repair of DNA caused
by oxidative and alkylation damage and thus protects cells against the toxic effects of
endogenous and exogenous agents including chemotherapeutic agents [57]. As importantly,
APE1/Ref-1 also functions as a reduction-oxidation (redox) factor maintaining transcription
factors in an active reduced state (reviewed in [36] and [58]). APE1/Ref-1 stimulates the DNA
binding activity of numerous transcription factors that are involved in cancer promotion and
progression such as AP-1 (fos/jun), NFκB, HIF-1α, CREB, p53 and others [36,58]. We believe
both of these activities have potential in sensitizing cancer cells to chemotherapeutic agents.
Without a capacity to repair their DNA, the tumor cells are forced to undergo apoptosis, and
without APE1/Ref-1's reducing activity on transcription factors, transcription factors are
unable to bind DNA thus preventing the propagation of growth signals.
APE1/Ref-1 is active in both LP- and SP-BER and interacts with several proteins involved in
both sides of the BER pathway including 8-oxoguanine DNA glycosylase (OGG1), X-ray cross
complementing-1 (XRCC1), proliferating cell nuclear antigen (PCNA), Flap endonuclease 1
(FEN1), and polymerase β (reviewed in [49]). Inhibitors of APE1/Ref-1's DNA repair function
is hypothesized to sensitize tumor cells to alkylating and oxidizing agents based on many
reports in the literature that demonstrate a reduction in the protein does just that, sensitize the
cells to agents that generate damage that APE1/Ref-1 acts upon. Targeted reduction of APE1/
Ref-1 protein by specific anti-sense oligonucleotides or siRNA renders mammalian cells
hypersensitive to methylmethane sulfonate (MMS), H2O2, bleomycin, TMZ, melphalan, and
gemcitabine [59-63]. The importance of APE1/Ref-1 to the cell is demonstrated by the lethality
of APE1/Ref-1 mouse knockouts at E3.5 to E9.5 and the lack of viable cell lines completely
deficient for APE1/Ref-1[64] and reviewed in[65]. Knocking out APE1/Ref-1 in the mouse or
in cancer cell lines using RNA interference or siRNA methodology emphasizes the importance
of its function to the survival and propagation of cells.
There are three compounds that have been reported as APE1/Ref-1 DNA repair inhibitors:
methoxyamine (MX), 7-Nitroindole-2-Carboxylic Acid (NCA), and lucanthone (Table 2). All
of these compounds enhance the cytotoxic potential of temozolomide in numerous cancer cell
lines (ovarian, breast, colon, fibrosarcoma) [53,54,66-69]. The mechanism behind the
enhancement of TMZ-induced cytotoxicity by MX is well-characterized and is not through
direct inhibition of APE1/Ref-1, but by a blockade of the BER pathway. Following the
glycosylase-driven removal of a damaged nucleotide, an abasic site is generated. MX, an
alkoxyamine derivative can bind to the acyclic sugar left in the DNA abasic site thereby
blocking the downstream members of the BER pathway, APE1/Ref-1 and β pol [70,71].
Perhaps even more dramatic results could be achieved with a direct inhibitor of the DNA repair
activity of APE1/Ref-1 with a reduction in the amount of off-target effects. Using a high
through-put screen, the NCA compound was discovered. In this published study, NCA
potentiates the activity of MMS, TMZ, H2O2, and Zeocin in HT1080 human fibrosarcoma cells
presumably through inhibition of the AP endonuclease, 3′-phosphodiesterase, 3′-phosphatase,
and 3′ to 5′-exonuclease activities of APE1/Ref-1 [68]. Finally a compound, lucanthone known
as a topoisomerase II inhibitor [72] also may have effects on the DNA repair activity of APE1/
Ref-1. A dose-dependent increase in AP sites following lucanthone treatment in breast cancer
cell lines [73] and potentiation of the cell killing effect of MMS and TMZ [69] support an
inhibition of APE1/Ref-1 by lucanthone. However, cytotoxicity following lucanthone
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treatment is presumably due more to inhibition of Topoisomerase II based on the doses that
are necessary for in vitro APE1/Ref-1 inhibition.
Not nearly as many efforts have been put toward discovering a redox inhibitor of APE1/Ref-1.
Partly because the importance and relevance of its redox function are just becoming apparent.
The anti-cancer potential of a redox inhibitor of APE1/Ref-1 is great. Transcription factors
including HIF-1α, p53, NFκB, CREB, and AP-1 have all been implicated in important aspects
of cancer including angiogenesis and tumor promotion and progression. Through inhibition of
APE1/Ref-1's redox activity these transcription factors would be unable to bind to DNA and
thereby tumor cell signaling of angiogenesis and uncontrolled growth would be slowed and/
or stopped. The following compounds have an effect on the redox activity of APE1/Ref-1: soy
isoflavones, resveratrol, and E3330 [43,74-77]. The dual functions of APE1/Ref-1 point to it
as an important target to sensitize tumor cells to chemotherapy [78]. Perhaps a drug that caused
a reduction in APE1/Ref-1 mRNA and/or protein levels would be potent and effective against
a growing tumor.
β-Pol
The polymerase responsible for DNA synthesis in SP-BER is β-pol. β-pol has associated lyase
activity that is important and often rate-limiting in BER, and β-pol also plays a role in single
nucleotide gap filling in LP-BER (reviewed in [79,80]), therefore it is a potential target for
potentiation of tumor cells to DNA damaging agents. Natural product, koetjapic acid interacts
with residues in the 8-kDa domain of β-pol which is responsible for its lyase activity and in
combination with NMR chemical shift mapping, was used to discover pamoic acid as a β-pol
inhibitor, both its lyase and polymerase activities [81]. Inhibition of β-pol with pamoic acid
sensitizes mouse fibroblasts to laboratory agent, MMS. β-pol is most likely not the most
attractive protein to target in cancer therapy based on the lack of sensitization of β-pol-null
cells to several chemotherapeutic agents, including melphalan, mitozolomide, BCNU, and IR
[82]. However these null cells are sensitive to TMZ [82-84].
PARP-1
Although not a direct part of the damage removal and base repair, poly (ADP) ribose
polymerase-1 (PARP-1) interacts with several BER proteins including β-pol, XRCC1, and
DNA Ligase III (reviewed in [49]) and acts as a sensor of DNA strand breaks. PARP-1 functions
by cleavage of NAD+ to add ADP-ribose units to DNA, histones, and various DNA repair
enzymes. This addition acts as a signal to many different cellular processes including
replication, transcription, protein degradation, spindle maintenance and others (Fig. 1B)
(reviewed in [85] and [86]). PARP-1 is just one member of a superfamily of poly (ADP-ribosyl)
polymerase enzymes with 17 members to date [87]. Knockout of PARP-1 is not embryonic
lethal, however double knockout of PARP-1 and -2 results in embryonic lethality around day
8 demonstrating the redundancy and overlapping roles of PARP-1 and -2 and their importance
to the developing embryo [88]. Overactivation of PARP can lead to cell death via necrosis and
apoptosis. Cellular depletion of NAD+ results in a necrotic cell death while PARP activation
also plays a role in apoptosis-inducing factor (AIF)'s release from the mitochondria [89]. When
PARP-1 is deficient or absent in cells, BER efficiency is greatly reduced [90]. Additionally,
pharmacologic inhibition of PARP-1 in cancer cell lines and knocking out PARP-1 and
PARP-2 in the mouse demonstrate that sensitization to alkylating agents, N-methyl-N-
nitrosourea (MNU) and chemotherapeutics including TMZ and IR is possible [8,88,91,92].
Several PARP-1 inhibitors are now under investigation as single agents and in combination
with TMZ (Table 2) (reviewed in [91]). In cells deficient in BRCA1 and BRCA2 (breast cancer
susceptibility proteins), PARP inhibitors are reported to be extremely efficacious [93-95]
presumably due to the combination of the lack of homologous recombination as a result of
BRCA deficiency and the lack of PARP signaling to repair the DNA strand breaks. These
Kelley and Fishel Page 6
Anticancer Agents Med Chem. Author manuscript; available in PMC 2009 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
findings suggest that selective tumor cell killing is possible in cancer cells that are defective
in BRCA1 and BRCA2. One report contradicts these data indicating that specific cell killing
in BRCA2 deficient cells is not achieved with PARP inhibitors, [96] however different cell
lines and PARP inhibitors with differing potency were used in these studies, which could
potentially lead to different effects on cell sensitivity [97]. Regardless of the specificity of
PARP inhibitors to kill only cancer cells with a predisposed DNA repair deficiency, PARP
inhibitors are an emerging class of chemotherapeutic agents that hopefully will have efficacy
against a range of cancers.
NUCLEOTIDE EXCISION REPAIR (NER) AND MISMATCH REPAIR (MMR)
There is little information on targeting the MMR or NER pathways for cancer therapeutics
(Fig. 2). One explanation for this centers on the relationship of genetic diseases that have been
shown to be linked to defects in NER (Xeroderma pigmentosum, Cockayne's Syndrome) and
MMR (Hereditary Non-polyposis Colon Cancer; HNPCC). Additionally, defective MMR has
demonstrated an increase in tumor cell resistance to cisplatin [98]. These findings make a case
that inhibiting NER or MMR enzymes may not be an appropriate approach. Alternatively, the
reactivation of MMR enzymes may be one approach to re-sensitize tumors to chemotherapy.
An example of this is the use of 2′-deoxy-5-azacytadine (decitabine) to reverse the methylation
of MMR genes such as MLH1. In one study, restoring MLH1 expression results in the
acquisition of cisplatin sensitivity [8,99]. This was also observed with 5-fluorouracil (5-FU)
treatments of colon cancer cells [100]. Clearly, MLH1 reactivation by dacitabine treatment is
not the only gene being reactivated so the actual mechanism of this newly acquired cisplatin
sensitivity may not be totally attributable to MLH1 re-activation.
NER and MMR have been implicated in cross-link DNA damage repair and are the presumed
major pathways for this type of DNA damage (Fig. 2). Most studies have focused on increasing
the sensitization of tumor cells to cisplatin or other platinum agents because they are so widely
used to treat many different kinds of cancer. One study used anti-sense RNA to ERCC1, a NER
enzyme, in combination with cisplatin and demonstrated an increase in ovarian cancer cell
killing [101]. Cisplatin-induced cytotoxicity is also enhanced with the addition of gemcitabine
presumably due to the blockage of cross-link repair. However, the link between this finding
and NER is unclear. A more direct link was observed using a global cyclin-dependent kinase
inhibitor (UCN-01; 7-hydroxystaurosporine) which has enhanced cisplatin tumor sensitivity
[102] and is in Phase I clinical trials [103]. This drug blocks the interaction between XPA
(Xeroderma pigmentosum group A) and ERCC1 (excision repair cross-complementing group
1) which has been implicated in the damage-recognition and/or incision steps of NER [104].
Similarly, the RPA protein (replication protein A) which is a single-stranded DNA binding
protein that is involved in chromosomal DNA replication, repair and recombination pathways
is being investigated as a potential target to enhance cisplatin sensitivity [105]. A number of
other small molecule inhibitors that target proteins involved in pathways other than DNA repair
result in the reduction in DNA repair response. For example, ZD1839 (Gefitinib or IRESSA)
which is an epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor actually
alters the DNA repair response and increases cisplatin cytotoxicity [106,107]. A similar result
is observed for VEGF (vascular epidermal growth factor) inhibitor, SU5416. This compound
causes a decrease in ERCC1 expression and increases cisplatin sensitivity [108,109]. How a
“specific” VEGF or EGFR-TK inhibitor causes altered DNA repair response or decreased
ERCC1 protein expression leading to enhanced cisplatin cytotoxicity is completely unknown
at this time [108]. As the signaling pathways that respond to DNA damage are elucidated, the
underlying mechanisms of a decrease in NER and/or MMR proteins following targeted
therapies such as SU5416 or ZD1839 will become more apparent. Perhaps it will then be
possible to design better inhibitors for proteins in the NER and MMR pathways.
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HOMOLOGOUS RECOMBINATION (HR), NON-HOMOLOGOUS END-JOINING
(NHEJ) AND DOUBLE-STRAND BREAK (DSB) REPAIR
HR corrects chromosome breaks that occur during the S/G2 portion of the cell cycle. Double
strand breaks are recognized by the MRN complex (Mre11, Rad50 and Nbs1) and recruits the
Ataxia telangiectasia (ATM) protein which regulates HR and cell-cycle checkpoints [4[. Cells
that are defective in ATM are easily killed by direct DSB forming agents such as IR,
radiomimetics, reactive oxygen species (ROS) or indirectly by alkylating agents. A number of
inhibitors such as Wortmannin, LY2940002 and caffeine (Table 2) inhibit ATM function, but
are not very specific, have off-target effects and inhibit a number of members of the PI3K
(phosphatidylinositol 3-kinase) family with numerous side effects [8]. A newer compound,
KU55933 (2-morpholin-4yl-6-thiaanthren-1-ylpyran-4-one) which appears to be a more
specific inhibitor works as an ATP competitive inhibitor of ATM. KU55933 blocks the
phosphorylation of numerous ATM targets including SMC1 (structural maintenance of
chromosome 1), NBS1 (Nijmegen Breakage Syndrome), p53 and histone-H2AX [110]. H2AX
has also become a target for therapeutics as initial data demonstrated that peptide inhibitors of
the γ̃H2AX demonstrated increased sensitivity to IR [111]. Initial data supports the use of
KU55933 in conjunction with chemotherapeutic agents camptothecin, doxorubicin and
etoposide [6,110] as well as IR [110].
The NHEJ pathway rejoins DNA double-strand breaks regardless of sequence homology or
not at the ends of the broken DNA in contrast to HR which requires sequence homology [4].
Furthermore, NHEJ appears to be the main pathway for the repair of DNA double-strand breaks
and is independent of cell cycle. Proteins involved in this pathway include Ligase 4, Artemis,
XRCC4, the Ku proteins, Ku70 and Ku80 and most importantly for this review, DNA-protein
kinase (DNA-PK). Most cells lacking DNA-PK, including mice, are hypersensitive to IR and
numerous DNA cross-linking agents. Various inhibitors are being developed targeting DNA-
PK such as NU7026 (Table 2) which sensitizes cells containing DNA-PK to IR [112]. DNA
PK inhibitors, IC87361 and IC87102 are effective in sensitizing tumor microvasculature and
tumor cells to IR [6]. Given the importance of repairing DNA double-strand breaks on tumor
cell survival and their relationship to IR, the search for inhibitors of members of this pathway,
including DNA-PK is important to pursue [5-8].
CONCLUSIONS
The identification of targets in pathways such as signaling pathways, multidrug resistance, cell
cycle checkpoints, anti-angiogenesis, and others have been prime areas of focus for molecular
biologists for a number of years. Attention to DNA repair pathways as potential targets has
lagged significantly. However, recent findings are starting to cause a sea of change in this area
of study. As demonstrated by the list of known DNA repair protein/enzyme inhibitors (Table
2), this field is clearly not saturated and ripe for further study and innovation. Lead targets such
as those that actually interact with the DNA and/or the DNA adduct including AGT, PARP
and APE1/Ref-1 show encouraging promise in translational studies. Other less direct targets,
such as the signaling molecules in DSB repair pathways, ATM and DNA-PK are also clearly
viable targets. Furthermore, numerous studies are identifying small nucleotide polymorphisms
(SNPs) in DNA repair enzymes and signaling molecules such that potential DNA repair
biomarkers can be coupled with therapeutic targets. This growing area is also showing great
promise. This accumulating body of evidence clearly demonstrates that selective targeting of
these DNA repair enzymes has the potential to enhance and augment the currently used
chemotherapeutic agents and radiation as well as overcoming drug resistance.
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Fig. 1.
Cartoon of two of the most promising DNA repair pathways for cancer therapeutics. A) The
direct reversal pathway is made up of the AGT protein and recognizes O6-alkylguanine lesions
in DNA. Clinically used inhibitor, O6-Benzylguanine (BG) acts as a pseudo-substrate and
inactivates AGT resulting in a persistence of DNA lesions and an increase in sensitivity to
agents that generate O6-lesions. B) The DNA base excision repair (BER) pathway is involved
in repairing DNA damage caused by alkylating and oxidizing DNA damaging agents as well
as ionizing radiation (IR). The DNA BER pathway is made of up both the short- and long-
patch sub-pathways with APE1/Ref-1 playing a crucial role in both. Proteins that are currently
good or potential targets for cancer therapeutics are shown in red letters.
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Fig. 2.
Schematic overview of mammalian DNA repair pathways. Proteins that are emerging as strong
lead targets for cancer therapeutics are shown with a blue background. Those that have little
data or data only generated in cell lines are shown circled in red. Not all members of each
pathway are shown.
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Table 1
Clinical Agents that Create DNA Lesions that are Repaired by Direct and Base
Excision Repair
Type of Damage Pathway Ref.
 Direct-Acting Agents
Temozolomide
O6-meG
N3-meA
N7-meG
Direct
BER
BER
[37]
Melphalan N3-meADNA cross-links
BER
NER [38]
Thiotepa Formamidopyrimidine7-Methyl-formamidopyrimidine
BER
BER [39]
Radiation
SSBs
DSBs
ROS
BER
HR / NHEJ
BER
[113]
BCNU / CCNU Chloroethyl adduct at O
6-G
DNA cross-links
Direct
NER/HR [42]
Dacarbazine / Procarbazine O
6-meG
N7-meG
Direct
BER [41]
Streptozotocin
O6-meG
N3-meA
N7-meG
Direct
BER
BER
[42]
 Indirect-Acting Agents
Platinum Agents
Oxaliplatin Inter-and intrastrand DNA crosslinksROS
NER / MMR / HR
BER
[114]
[43]
Cisplatin Inter- and intrastrand DNA crosslinksROS
NER / MMR / HR
BER
[114]
[43]
Anthracyclines [45]
Epirubicin ROS BER
Daunorubicin ROS BER
Doxorubicin ROS BER [115]
Nucleoside analogs
Gemcitabine / Troxacitabine L-configuration nucleoside analogs BER [116]
    Other
Paclitaxel Microtubule stabilizationROS BER [47]
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Table 2
DNA Repair Inhibitors
Direct (AGT) BER Others Related to DNA Repair
06BG Methoxyamine Ape1 repair IC 87361 DNA-PK
06-benzyl-2'-deoxyguanosine E3330 Ape1 redox IC87102 DNA-PK
06-4 Bromethenyl-guanine (06-BTG) Lucanthone Ape1 repair / Topo II NU7441 DNA-PK
06-4 Bromethenyl-guanine-(C8-β-d-glucoside) KJA β-polymerase NU7026 DNA-PK
Lomeguatrib
[6-(4-bromo-2-thienyl) methoxy]-purin-2-amine]
Pamoic Acid β-polymerase OK-1035 DNA-PK
CRT0044876 Ape1 repair SU11752 DNA-PK
Nu1025 Vanillin DNA-PK
Nu1064 Salvicine DNA-PKcs
Nu1085 Ku55933 ATM Kinase
AG14361 LY294002 ATM Kinase
AG14699 PARP Wortmannin ATM Kinase
GPI15427
CEP6800 PARP
INO-1001 PARP
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